Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced it will report its first quarter 2022 financial results on May 4, 2022, after market close. The conference call is set to begin at 1:30 p.m. Pacific Time. Investors can access the live webcast on the company's website, which will also be archived for later listening. Adaptive Biotechnologies focuses on the adaptive immune system's genetics to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. The company currently has three commercial products and a strong clinical pipeline.

Positive

• Three commercial products available for market.
• Robust clinical pipeline addressing cancer and autoimmune diseases.

Negative

• None.

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in our Immune Medicine and Minimal Residual Disease (MRD) businesses. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Laura Cooper, Senior Director, Corporate Communications
206-693-2042
lcooper@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its Q1 2022 financial results?

Adaptive Biotechnologies will report its Q1 2022 financial results on May 4, 2022, after market close.

What time is the Adaptive Biotechnologies Q1 earnings call?

The earnings call will begin at 1:30 p.m. Pacific Time on May 4, 2022.

Where can I access the Adaptive Biotechnologies earnings call webcast?

The earnings call webcast can be accessed in the 'Investors' section of the Adaptive Biotechnologies website.

What products does Adaptive Biotechnologies offer?

Adaptive Biotechnologies has three commercial products aimed at diagnosing and treating diseases.